The safety analysis of lurasidone based on the real-world data of FAERS database
This study reveals known and unexpected AEs about lurasidone, related to the eye, lactating women and life-threatening threats, and underscores the need for ongoing post-marketing surveillance of lurasidone.
Authors
- Weijian Liang
- Yi Du (ORCID: https://orcid.org/0000-0001-9568-0907)
- Mengting Zhang (ORCID: https://orcid.org/0009-0002-0301-4371)
- Chun Yang (ORCID: https://orcid.org/0000-0001-5813-0914)
- Yongshuai Jiang (ORCID: https://orcid.org/0000-0002-7163-6554)
- Lei Xi (ORCID: https://orcid.org/0000-0002-5445-8557)
- Jinfeng Zhu (ORCID: https://orcid.org/0000-0002-1737-0185)
- Ziyi Luo (ORCID: https://orcid.org/0009-0009-8363-5581)
- Zhenjie Wang (ORCID: https://orcid.org/0000-0003-1717-5790)
- Mianda Hu
- Yi Liu (ORCID: https://orcid.org/0009-0003-6743-6415)
Institutions
- Guangdong Medical College (CN)
- Third Affiliated Hospital of Southern Medical University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1080/14740338.2025.2498054
- Primary Topic
- Bipolar Disorder and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Guangdong Province